中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

52 records (took 0.041 seconds)

    High affinity human antibodies to tumor antigens
    3.
    发明授权
    High affinity human antibodies to tumor antigens 失效
    抗人肿瘤抗原的高亲和力

    公开(公告)号：US5977322A

    公开(公告)日：1999-11-02

    申请号：US665202

    申请日：1996-06-13

    Applicant: James D. Marks ,  Robert Schier

    Inventor： James D. Marks ,  Robert Schier

    IPC: A61K38/00 ,  C07K16/32 ,  C12P21/08 ,  G01N33/574 ,  C07K16/30

    CPC classification number: C07K16/32 ,  F16H59/105 ,  F16H61/32 ,  G01N33/57492 ,  A61K2039/505 ,  A61K38/00 ,  C07K2317/21 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/626 ,  C07K2317/77 ,  C07K2317/92 ,  C07K2319/00 ,  F16H2061/326 ,  G01N2333/71

    Abstract: This invention provides novel human antibodies that specifically bind to human c-erbB-2. In one embodiment, the antibodies are single chain antibodies initially developed by phage display against a c-erbB-2 target. The resulting antibodies (designated C6 antibodies) show improved specificity and affinity for c-erbB-2. In addition, since the C6 antibodies are both relatively small and fully human they are less immunogenic in humans than other (e.g., full-size or chimeric) anti-c-erbB-2 antibodies. The C6 antibodies may be used alone or as components of chimeric molecules that specifically target and deliver effector molecules to cells overexpressing c-erbB-2.

    Abstract translation: 本发明提供了特异性结合人c-erbB-2的新型人抗体。 在一个实施方案中，抗体是最初通过针对c-erbB-2靶的噬菌体展示而开发的单链抗体。 所得抗体（指定为C6抗体）显示出对c-erbB-2的特异性和亲和性的改善。 此外，由于C6抗体相对较小并且完全人类，因此它们在人类中的免疫原性比其他（例如，全尺寸或嵌合）抗c-erbB-2抗体的免疫原性较小。 C6抗体可以单独使用或作为嵌合分子的组分使用，其特异性靶向并将效应分子递送至过量表达c-erbB-2的细胞。

    Prostate cancer specific internalizing human antibodies
    8.
    发明授权
    Prostate cancer specific internalizing human antibodies 有权
    前列腺癌特异性内化人抗体

    公开(公告)号：US07582736B2

    公开(公告)日：2009-09-01

    申请号：US11972130

    申请日：2008-01-10

    Applicant: Bin Liu ,  James D. Marks

    Inventor： Bin Liu ,  James D. Marks

    IPC: C12P21/08

    CPC classification number: C07K16/3069 ,  A61K2039/505 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/77

    Abstract: This invention provides novel prostate cancer specific internalizing human antibodies. The antibodies are useful by themselves to prevent growth and/or proliferation of prostate cancer cells. The antibodies can also be formulated as chimeric molecules to direct an effector (e.g. a cytotoxin, an imaging reagent, a drug, etc.) to a prostate tumor site.

    Abstract translation: 本发明提供了新型前列腺癌特异性内化人抗体。 抗体本身可用于预防前列腺癌细胞的生长和/或增殖。 抗体还可以配制成嵌合分子以将效应物（例如细胞毒素，成像试剂，药物等）引导至前列腺肿瘤部位。

    Prostate cancer specific internalizing human antibodies
    10.
    发明授权
    Prostate cancer specific internalizing human antibodies 有权
    前列腺癌特异性内化人抗体

    公开(公告)号：US07335744B2

    公开(公告)日：2008-02-26

    申请号：US11021438

    申请日：2004-12-21

    Applicant: Bin Liu ,  James D. Marks

    Inventor： Bin Liu ,  James D. Marks

    IPC: C12P21/08

    CPC classification number: C07K16/3069 ,  A61K2039/505 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/77

    Abstract: This invention provides novel prostate cancer specific internalizing human antibodies. The antibodies are useful by themselves to prevent growth and/or proliferation of prostate cancer cells. The antibodies can also be formulated as chimeric molecules to direct an effector (e.g. a cytotoxin, an imaging reagent, a drug, etc.) to a prostate tumor site.

    Abstract translation: 本发明提供了新型前列腺癌特异性内化人抗体。 抗体本身可用于预防前列腺癌细胞的生长和/或增殖。 抗体还可以配制成嵌合分子以将效应物（例如细胞毒素，成像试剂，药物等）引导至前列腺肿瘤部位。

Patent Agency Ranking